OphSourceHomeJournal CollectionOphSource ShopEvents
Journal Home
Search for

Volume 110, Issue 5, Pages 895-899 (May 2003)


View previous. 18 of 46 View next.

Long-term results of noncontact neodymium:yttrium–aluminum–garnet cyclophotocoagulation in neovascular glaucoma1

Presented as a poster at the American Academy of Ophthalmology, New Orleans, Louisiana, November 2001.

Maria F Delgado, MD1, Christopher J Dickens, MD1Corresponding Author Informationemail address, Andrew G Iwach, MD1, Gary D Novack, PhD2, Diana S Nychka, OD1, Patricia C Wong, MD1, Ngoc Nguyen, MD1

Received 24 December 2001; accepted 18 September 2002.

Abstract 

Purpose

To determine the long-term efficacy and safety of noncontact transscleral neodymium:yttrium–aluminum–garnet (Nd:YAG) cyclophotocoagulation (CP) for the treatment of neovascular glaucoma (NVG).

Design

Retrospective, noncomparative, interventional case series.

Participants

One hundred fifteen eyes of 111 subjects treated from December 1987 to January 2001.

Methods

Eyes with uncontrolled NVG underwent noncontact Nd:YAG CP. Treatment parameters and pretreatment and posttreatment intraocular pressures (IOP) were reviewed. Preoperative and postoperative IOP were compared using a paired Student’s t test. Success was defined as an IOP ≤22 mmHg, with or without medications, in the absence of phthisis bulbi, and without having undergone further surgical procedures. Results were subjected to a Kaplan–Meier life-table analysis.

Results

Mean follow-up was 27.0 ± 34.3 months (range, 1–148 months). Mean preoperative IOP was 47.4 ± 11.1 mmHg (range, 26–70 mmHg). Mean postoperative IOP was 18.3 ± 12.2 mmHg (range, 0–44 mmHg). The mean number of treatment sessions was 1.4 ± 0.7 (range, 1–6), with 82 eyes (71.3%) having only one treatment. Kaplan–Meier survival analysis showed a probability of continued success at 1 year of 65.0%, at 3 years of 49.8%, and at 6 years of 34.8%. Phthisis developed in 8.6% of the eyes.

Conclusions

Noncontact Nd:YAG CP provides long-term IOP reduction in eyes with medically uncontrolled NVG. This can be associated with complications that include inflammation, visual loss, and hypotony. Repeat treatment may be necessary.

1 Glaucoma Research & Education Group, San Francisco, California, USA

2 PharmaLogic Development, Inc., San Rafael, California, USA

Corresponding Author InformationReprint requests to Christopher J. Dickens, MD, 490 Post Street, Suite 644, San Francisco, CA 94102, USA.

 Manuscript no. 211058.

Supported by the Glaucoma Research Foundation, San Francisco, CA.

1 The authors have no proprietary interest in any of the equipment or materials mentioned in this article.

PII: S0161-6420(03)00103-9

doi:10.1016/S0161-6420(03)00103-9


View previous. 18 of 46 View next.